Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2026
Prognostic significance of TOP2A expression in bladder cancer: Systematic review and meta-analysis.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hendri Ahmad Zulfan, Robert Robert, Febriyanto Toni, Liliana Belinda, Pratama Angga Dewa Megatika, Oey Oliver
Аннотация
INTRODUCTION: Elevated topoisomerase IIA (TOP2A) expression is consistently linked to poor prognosis, driving cancer progression through its role in DNA unlinking. Although TOP2A is well-established in other cancers, its prognostic value in bladder cancer remains unclear. This study was conducted to assess the prognostic significance of TOP2A for patients with bladder cancer.
METHODS: PubMed, EMBASE (Ovid), and the Cochrane Library were systematically searched to identify studies published up to August 8, 2024. Published studies reporting the prognosis of patients with bladder cancer stratified by TOP2A expression were included. A random-effect model was used to pool the standardized mean difference (SMD) with 95% confidence interval (CI) for tumor stage and grade and hazard ratio (HR) with 95% CI for cancer-specific survival (CSS). The Newcastle-Ottawa Quality (NOS) was used to assess the risk of bias in the included studies.
RESULTS: Nine studies with 1764 eligible patients with bladder cancer were identified. TOP2A expression was found in 32% patients with bladder cancer. High TOP2A expression was significantly correlated with higher tumor grade (SMD 1.61, 95% CI -0.02-3.23, p=0.05), higher tumor stage (SMD 1.09, 95% CI 0.01-2.17, p=0.05), and worse CSS (HR 1.19, 95% CI 1.05-1.36, p=0.008) in patients with bladder cancer.
CONCLUSIONS: TOP2A expression shows potential as a prognostic biomarker in bladder cancer; however, significant heterogeneity in study design, measurement methods, and analytical approaches limits the strength of the current evidence. Further prospective studies with standardized biomarker assessment are warranted to validate its clinical utility.
METHODS: PubMed, EMBASE (Ovid), and the Cochrane Library were systematically searched to identify studies published up to August 8, 2024. Published studies reporting the prognosis of patients with bladder cancer stratified by TOP2A expression were included. A random-effect model was used to pool the standardized mean difference (SMD) with 95% confidence interval (CI) for tumor stage and grade and hazard ratio (HR) with 95% CI for cancer-specific survival (CSS). The Newcastle-Ottawa Quality (NOS) was used to assess the risk of bias in the included studies.
RESULTS: Nine studies with 1764 eligible patients with bladder cancer were identified. TOP2A expression was found in 32% patients with bladder cancer. High TOP2A expression was significantly correlated with higher tumor grade (SMD 1.61, 95% CI -0.02-3.23, p=0.05), higher tumor stage (SMD 1.09, 95% CI 0.01-2.17, p=0.05), and worse CSS (HR 1.19, 95% CI 1.05-1.36, p=0.008) in patients with bladder cancer.
CONCLUSIONS: TOP2A expression shows potential as a prognostic biomarker in bladder cancer; however, significant heterogeneity in study design, measurement methods, and analytical approaches limits the strength of the current evidence. Further prospective studies with standardized biomarker assessment are warranted to validate its clinical utility.